Brought to you by 
Notes offering brings $607.2mm in net proceeds to Dendreon
10 Nov 2014
Executive Summary
Dendreon Corp. (immunotherapies for cancer) netted $607.2mm (including the overallotment) through the public offering of 2.875% senior notes due January 15, 2016. The notes convert into cash or common shares (or a combination of both) at the election of the company. The conversion rate of $19.52 per 1k principal amount of notes equates to about $51.42 per common share. (Dendreon's stock averaged $36.34 at the time of the initial offering announcement.)
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Notes offering brings $607.2mm in net proceeds to Dendreon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice